Le Lézard
Classified in: Health
Subject: SVY

Atopic Dermatitis (AD) -Epidemiology Forecast to 2025


NEW YORK, Nov. 17, 2017 /PRNewswire/ -- DelveInsight "Atopic Dermatitis (AD) - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Atopic Dermatitis (AD) in seven major markets (US, France, Germany, Italy, Spain, UK and Japan).

Read the full report: https://www.reportlinker.com/p05144676


It includes 10 years epidemiology historical and forecasted data of Atopic Dermatitis (AD) prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with the Atopic Dermatitis (AD). The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by DelveInsight team of industry experts.

Scope of the Report
The Report includes the prevalent population and how will it change over the next eight years.
Prevalent or incident cases segmented by age and sex.
Coverage of key Atopic Dermatitis (AD) subpopulations and its prevalent or incident cases
The key differences in epidemiology patterns across the seven market segments

Key Coverage and Benefits
The report will help in developing business strategies by understanding the trends shaping and driving the global Atopic Dermatitis (AD) market.
Identifying prevalent patient populations as well as risk factors in the global Atopic Dermatitis (AD) market will help to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the best opportunities for Atopic Dermatitis (AD) therapeutics in each of the markets covered.

Read the full report: https://www.reportlinker.com/p05144676

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker


These press releases may also interest you

26 avr 2024
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

26 avr 2024
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

26 avr 2024
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

26 avr 2024
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

26 avr 2024
David J. Dykeman, co-chair of the Life Sciences & Medical...

26 avr 2024
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...



News published on and distributed by: